Results 341 to 349 of about 7,109,986 (349)

A phase II trial of lenalidomide plus rituximab in previously untreated follicular non-Hodgkin’s lymphoma (NHL): CALGB 50803 (Alliance)

Annals of Oncology, 2017
Peter Martin
exaly  

Bortezomib plus rituximab versus rituximab alone in patients with relapsed, rituximab-naive or rituximab-sensitive, follicular lymphoma: a randomised phase 3 trial

Lancet Oncology, The, 2011
Evgenii A Osmanov, Fritz Offner, Jan A Walewski   +2 more
exaly  

Luteal phase defects: treatment during the follicular phase

1996
Nappi C, Palomba S, Pellicano M, Morgera R, Regine V, Di Carlo C   +5 more
openaire   +1 more source

Tafasitamab, lenalidomide, and rituximab in relapsed or refractory follicular lymphoma (inMIND): a global, phase 3, randomised controlled trial

Lancet, The
Javier López Jiménez, Juan-Manuel Sancho, Marek Trneny   +2 more
exaly  

Results of a phase I/II study of ocrelizumab, a fully humanized anti-CD20 mAb, in patients with relapsed/refractory follicular lymphoma

Annals of Oncology, 2010
John F Seymour
exaly  

Epcoritamab, lenalidomide, and rituximab versus lenalidomide and rituximab for relapsed or refractory follicular lymphoma (EPCORE FL-1): a global, open-label, randomised, phase 3 trial

Lancet, The
Marcel Nijland, Kim M Linton, Emmanuel Bachy   +2 more
exaly  

Effect of menstrual phase on surgical treatment of breast cancer

Lancet, The, 1994
exaly  

Progesterone in Follicular Phase during Controlled Ovarian Stimulation

2015
Sejal Naik, Sunita Tandulwadkar
openaire   +1 more source

Increased miscarriage rates following follicular-phase endometrial scratching

2019
Mackens, S., Racca, A., Van De Velde, H., Tournaye, H., Stoop, D., Blockeel, C., Santos-Ribeiro, S.   +6 more
openaire   +1 more source